Nektar Therapeutics (NKTR)
Automate Your Wheel Strategy on NKTR
With Tiblio's Option Bot, you can configure your own wheel strategy including NKTR - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol NKTR
- Rev/Share 4.4437
- Book/Share 6.0399
- PB 6.5746
- Debt/Equity 1.0803
- CurrentRatio 4.2411
- ROIC -0.38
- MktCap 807764499.0
- FreeCF/Share -13.5122
- PFCF -4.2436
- PE -4.6333
- Debt/Assets 0.305
- DivYield 0
- ROE -3.5681
- Rating D+
- Score 1
- Recommendation Strong Sell
- P/E Score 1
- DCF Score 1
- P/B Score 1
- D/E Score 1
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Initiation | NKTR | Citigroup | -- | Buy | -- | $102 | Nov. 26, 2025 |
| Reiterated | NKTR | H.C. Wainwright | -- | Buy | $6.5 | $120 | June 24, 2025 |
| Reiterated | NKTR | BTIG Research | -- | Buy | $60 | $100 | June 24, 2025 |
| Upgrade | NKTR | Jefferies | Hold | Buy | -- | $2 | April 11, 2025 |
| Upgrade | NKTR | Oppenheimer | Perform | Outperform | -- | $6 | March 14, 2025 |
| Initiation | NKTR | B. Riley Securities | -- | Buy | -- | $4 | Jan. 8, 2025 |
| Initiation | NKTR | H.C. Wainwright | -- | Buy | -- | $6.5 | Dec. 10, 2024 |
| Resumed | NKTR | BTIG Research | -- | Buy | -- | $4 | Sept. 30, 2024 |
News
Nektar Therapeutics Announces Completion of Target Enrollment in REZOLVE-AA Phase 2b Clinical Trial of Rezpegaldesleukin in Patients with Severe-to-Very Severe Alopecia Areata
Published: February 26, 2025 by: PRNewsWire
Sentiment: Neutral
SAN FRANCISCO , Feb. 26, 2025 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) today announced the company has completed target enrollment in its REZOLVE-AA Phase 2b study of rezpegaldesleukin in patients with severe-to-very-severe alopecia areata. Rezpegaldesleukin is an investigational biologic therapy that targets the interleukin-2 receptor complex in the body in order to stimulate proliferation of inhibitory immune cells known as regulatory T cells (Tregs).
Read More
Nektar Announces Clinical Trial Agreement to Evaluate Rezpegaldesleukin in Patients with New Onset Type 1 Diabetes Mellitus
Published: February 24, 2025 by: PRNewsWire
Sentiment: Neutral
-- TrialNet to conduct the Phase 2 randomized, placebo-controlled clinical study -- SAN FRANCISCO and NEW YORK , Feb. 24, 2025 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) and TrialNet, an international clinical trial network at the forefront of diabetes research, today announced a new collaboration agreement to evaluate Nektar's rezpegaldesleukin in patients with new onset stage 3 type 1 diabetes mellitus (T1D). Rezpegaldesleukin is a novel agonistic T regulatory (Treg) cell biologic that is designed to both dampen the inflammatory response and simultaneously restore immune balance by directly expanding functional Treg cells and engaging multiple immunoregulatory pathways.
Read More
Nektar Therapeutics to Host Virtual Investor & Analyst Event with Type 1 Diabetes Experts on February 24th
Published: February 24, 2025 by: PRNewsWire
Sentiment: Neutral
SAN FRANCISCO , Feb. 24, 2025 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) today announced that it will host a virtual investor and analyst event with Type 1 Diabetes (T1D) Experts on Monday, February 24, 2025 at 3:00 p.m. EST / 12:00 p.m.
Read More
Nektar Therapeutics Receives Fast Track Designation for Rezpegaldesleukin for the Treatment of Moderate-to-Severe Atopic Dermatitis
Published: February 10, 2025 by: PRNewsWire
Sentiment: Neutral
SAN FRANCISCO , Feb. 10, 2025 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for rezpegaldesleukin for the treatment of adult and pediatric patients 12 years of age and older with moderate-to-severe atopic dermatitis whose disease is not adequately controlled with topical prescription therapies or when those therapies are not advisable. Rezpegaldesleukin is an investigational biologic therapy that targets the interleukin-2 receptor complex in the body in order to stimulate proliferation of inhibitory immune cells known as regulatory T cells (Tregs).
Read More
About Nektar Therapeutics (NKTR)
- IPO Date 1994-05-03
- Website https://www.nektar.com
- Industry Biotechnology
- CEO Howard W. Robin
- Employees 61